Dehydration on GLP-1: Labs, Warning Signs, and Next Steps

Why GLP-1 drugs can lead to fluid loss

GLP-1 receptor agonists are prescription medicines that activate the GLP-1 receptor. The labels describe GLP-1 receptors in brain regions that regulate appetite, and the Wegovy and Foundayo labels say the drugs delay gastric emptying [1][2]. Nausea, vomiting, diarrhea, and constipation are the most common side effects of the class.

In the Wegovy 2.4 mg trials, which ran up to 68 weeks, nausea occurred in 44%, diarrhea in 30%, vomiting in 24%, and constipation in 24%, against 16%, 16%, 6%, and 11% with placebo [1]. At the 17.2 mg Foundayo dose over 72 weeks, nausea was 35%, diarrhea 25%, vomiting 24%, and constipation 24%, against 10%, 11%, 4%, and 9% with placebo [2]. The Wegovy label states that rates from separate trials cannot be compared directly [1].

The Foundayo label notes that nausea, vomiting, and diarrhea were more frequent during dose escalation and decreased over time [2]. Treatment was stopped for side effects by 6.8% of people on Wegovy 2.4 mg versus 3.2% on placebo [1], and by 8% on Foundayo versus 3% on placebo [2].

The kidney warning, in the labels' words

The Wegovy warnings section is titled Acute Kidney Injury Due to Volume Depletion and directs monitoring of kidney function in patients reporting reactions that could lead to volume depletion [1].

The Foundayo label says there have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Foundayo. It states that the majority of events occurred in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea, and it directs monitoring of kidney function in patients reporting reactions that could cause volume depletion, especially during initiation and escalation [2].

In the pooled Foundayo weight-management trials, acute kidney injury was reported in 0.2% of treated patients compared with 0.05% of those on placebo [2].

Which labs are used

The Wegovy and Foundayo labels call for kidney-function monitoring but do not specify a lab panel [1][2].

A basic metabolic panel reports sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, and glucose. Creatinine is the value that reflects how well the kidneys are filtering. The Foundayo volume-depletion section gives no numeric cutoff for dehydration [2].

Signs that fluid loss is affecting circulation

Dizziness is a listed adverse reaction: 8% with Wegovy 2.4 mg versus 4% with placebo [1]. In the pooled Foundayo trials, low blood pressure was reported in 2% of patients versus 0.5% on placebo. It was reported in 4% of Foundayo-treated patients who were also on blood pressure medication and in 1% of those who were not [2].

Gastrointestinal illness severe enough to cause dehydration is the setting the Foundayo label links to kidney injury [2].

The labels also flag persistent severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, as the pancreatitis picture; the labels say to discontinue the drug if pancreatitis is suspected [1][2]. Severe gastrointestinal reactions are a labeled warning, and the drugs are not recommended in people with severe gastroparesis [1][2].

What the labels say about dosing after symptoms or missed doses

The Wegovy label says to consider delaying dosage escalation if needed, and that if two or more consecutive doses of the weekly injection are missed, dosage escalation is reinitiated at a lower dose to reduce the risk of gastrointestinal adverse reactions [1]. The Foundayo label applies a similar rule to its daily tablets: a missed dose can be taken as soon as possible without doubling the next one, and if seven or more consecutive doses are missed, escalation restarts at a lower dose [2].

For fluids, the WHO document on oral rehydration salts describes a glucose-electrolyte solution used to prevent and treat dehydration from diarrhea in all but the most severe cases [3]. That document was written for diarrheal illness generally, not for GLP-1 patients specifically.